Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pfizer Consolidates Cambridge Research
by Rick Mullin
April 22, 2013
| A version of this story appeared in
Volume 91, Issue 16
Pfizer plans to relocate as many as 530 employees from its Cambridge North research center—a campus in Cambridge, Mass., the firm acquired in 2009 as part of Wyeth—to a research facility the firm leases in Cambridge’s Kendall Square. The company says the move is intended to concentrate its research efforts in one location and consolidate its Cambridge real estate. Pfizer has closed or downsized major research sites in England and Connecticut in recent years as it shifted its R&D focus to Cambridge.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X